Duvortuxizumab

{
  "id": "MLC-T-ONC-013189",
  "term": "Duvortuxizumab",
  "field": "Oncology and biomedicine",
  "definition": "An anti-CD19/anti-CD3 bispecific, humanized antibody-like protein, with potential immunostimulatory and antineoplastic activities. Duvortuxizumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon administration, duvortuxizumab binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during normal B-cell development and on B-cell malignancies.",
  "synonyms": [
    "CD19 x CD3 DART protein JNJ-64052781",
    "hBU12(2.4)-hXR32-MP3 M1.2"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/duvortuxizumab/"
}